866-997-4948(US-Canada Toll Free)

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 79 Pages

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Beta Secretase 1 - Pipeline Review, H2 2017'; Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 27 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.

The report 'Beta Secretase 1 - Pipeline Review, H2 2017' outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 2 and 11 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease, Mild Cognitive Impairment and Neurodegenerative Diseases.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
- The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview 8
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development 21
Allgenesis Biotherapeutics Inc 21
Amgen Inc 21
AstraZeneca Plc 22
Bristol-Myers Squibb Co 22
Eisai Co Ltd 23
Eli Lilly and Co 23
Genentech Inc 24
H. Lundbeck A/S 24
Johnson & Johnson 25
Merck & Co Inc 25
Novartis AG 26
Pfizer Inc 26
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles 28
AG-12896 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AMG-8718 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AVCRI-104P3 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AVCRI-175P1 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CNP-520 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
elenbecestat - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ER-901356 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GNE-892 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
JNJ-1911 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lanabecestat camsylate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
LuAF-66432 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
LY-2811376 + LY-3002813 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LY-3202626 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
PF-06751979 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Inhibit BACE 1 for Alzheimers Disease - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Inhibit BACE1 for Alzheimers Disease - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TAK-070 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
verubecestat - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products 64
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products 65
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones 66
Featured News & Press Releases 66
Jul 17, 2017: Eisai Presents 3 Posters On Elenbecestat at the 2017 Alzheimer Association International Conference 66
Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan 67
Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy 67
Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimers Disease 68
Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisais Bace Inhibitor E2609 For Early AlzheimerS Disease 69
Nov 02, 2016: Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine 70
Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease 71
Aug 22, 2016: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease 71
Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimers Disease to Phase III 72
Jun 14, 2016: New Alzheimers Study Aimed at Preventing or Delaying Symptoms 73
Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimers disease 74
Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers disease 74
Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimers disease 75
May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug 76
Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimers Disease Therapy, MK-8931 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indication, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Pipeline by Allgenesis Biotherapeutics Inc, H2 2017 21
Pipeline by Amgen Inc, H2 2017 21
Pipeline by AstraZeneca Plc, H2 2017 22
Pipeline by Bristol-Myers Squibb Co, H2 2017 22
Pipeline by Eisai Co Ltd, H2 2017 23
Pipeline by Eli Lilly and Co, H2 2017 24
Pipeline by Genentech Inc, H2 2017 24
Pipeline by H. Lundbeck A/S, H2 2017 25
Pipeline by Johnson & Johnson, H2 2017 25
Pipeline by Merck & Co Inc, H2 2017 26
Pipeline by Novartis AG, H2 2017 26
Pipeline by Pfizer Inc, H2 2017 27
Dormant Projects, H2 2017 64
Discontinued Products, H2 2017 65

List of Figures
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Indications, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Molecule Types, H2 2017 19
Number of Products by Stage and Molecule Types, H2 2017 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *